Tracking Tysabri Treatment: A Medical Records Checklist for PML Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Awareness

If you or a loved one is taking Tysabri, tracking every MRI and symptom note is essential for PML vigilance. Building on decades of clinical experience with disease-modifying therapies, this checklist helps you organize key medical records to support informed conversations with your healthcare team.

Understanding Tysabri and the Risk of PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three factors that increase risk: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In the FDA Adverse Event Reporting System (FAERS) database, adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with those of multiple sclerosis itself, which can delay recognition of PML. The label emphasizes that PML usually leads to death or severe disability, underscoring the gravity of this adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors

Mechanistically, Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking adhesion molecules on immune cells and preventing their migration into the central nervous system. This immunosuppressive effect in the brain is thought to allow reactivation of latent JC virus, leading to PML. The label notes that prior use of immunosuppressants further elevates risk, and that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of therapy is a critical factor, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Massachusetts who have developed PML after Tysabri exposure, legal considerations include the statute of limitations for filing a claim. In Massachusetts, the statute of limitations for personal injury actions is generally three years from the date the injury is discovered or reasonably should have been discovered. For medical product liability claims, this timeline may begin when the patient or their representative becomes aware of the link between Tysabri and PML. The adequacy of warnings is a central issue: the Tysabri label includes a boxed warning about PML risk, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the specific risk factors, and the need for vigilant monitoring. The label states that physicians should consider whether the expected benefit of Tysabri is sufficient to offset the PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, if a patient was not informed about the risk factors—such as anti-JCV antibody status or the increased risk after two years—or if monitoring was inadequate, the warning may be deemed insufficient.

Legal Timeline and Statute of Limitations in Massachusetts

The timeline between Tysabri exposure and documented harm is variable. PML can develop months to years after starting therapy, and symptoms may be subtle initially. The label instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis can worsen outcomes, as early intervention—such as plasma exchange to remove Tysabri from the circulation—may improve prognosis. For affected patients, consulting an attorney experienced in pharmaceutical litigation is advisable to evaluate the specific circumstances, including the date of diagnosis, the duration of Tysabri use, and the presence of any prior immunosuppressant use. The statute of limitations in Massachusetts requires prompt action once the injury is discovered, and evidence of inadequate warnings or failure to monitor may support a claim. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in its labeling. Patients who develop PML face severe disability or death. For Massachusetts residents, the statute of limitations for legal action is typically three years from discovery of the injury. The adequacy of warnings and the timeline of exposure and harm are critical factors in evaluating potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury actions is generally three years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-related PML claims, this timeline typically begins when the patient or their representative becomes aware of the link between Tysabri and PML. It is crucial to consult an attorney promptly to ensure compliance with this deadline.

What factors increase the risk of PML with Tysabri?

According to the Tysabri prescribing information, three factors increase the risk of PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should discuss these risk factors with their healthcare provider.

What are the early symptoms of PML?

Early symptoms of PML can include progressive weakness, gait disturbance, cognitive impairment, visual changes, and other neurological deficits. These symptoms often overlap with multiple sclerosis, which can delay diagnosis. Immediate medical evaluation is recommended if any new neurological symptoms appear during Tysabri treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.